Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders

This is data from a 26 week long randomized, double-blind, placebocontrolled clinical trial, investigating the effects of semaglutide 1.0 mg once weekly vs placebo, on early-stage metabolic abnormalities in individuals with schizophrenia Sprectrum disorders treated with olanzapine or clozapine. Clinicaltrials.gov NCT: NCT04892199, UTN: U1111-1232-3637, EudraCT: 2020-000102-28, CTIS: 2024-518746-24-00.

The protocol has been published previously: Sass MR, Danielsen AA, Köhler-Forsberg O, et al. Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry). BMJ Open 2023;13(1).

Treatmentcode: 1=semaglutide, 2=placebo

Abbreviations: CGI-S, Clinical Global Impression - Severity scale; BP, Blood pressure; FTND, Fagerströms Test for Nicotine Dependence; AUDIT, Alcohol Use Disorders Identification Test; DUDIT, Drug Use Disorders Identification Test; GAP-D, Global Assessment of Psychosocial Disability; SQLS, Schizophrenia Quality of Life; PANNS-6, Positive and Negative Syndrome Scale.

9999=NA

DXA data and activitysensor data is available pr request